Drug intelligence / Profile preview

TRC041266

Development stage: Discontinued
Lead developer: Torrent Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

TRC041266 is a synthetic co-crystal of TRC4186, designed to improve the bioavailability of the parent compound. It is primarily aimed at managing heart failure with left ventricular ejection fraction (LVEF) ≥40% in diabetic patients. The drug acts as an Advanced Glycosylation End-product (AGE) receptor antagonist, specifically targeting the AGE-specific receptor (AGER). It was developed by Torrent Pharmaceuticals.

Targets

AGER (RAGE)

Beyond the preview

Go deeper on TRC041266.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TRC041266.

Explore the full profile